Table 1 Patient characteristics of all 108 NSCLC patients treated with SRT concurrent to TT/IT
N (%), median (range) | |
|---|---|
All patients (n = 108) | |
Age (years) | 63 (33–80) |
Histology subtype | |
ADC | 80 (74) |
LCNEC | 3 (3) |
SqCC | 6 (6) |
Adenosquamous | 3 (3) |
Unknown | 16 (15) |
Synchronous metastatic disease | |
Yes | 81 (75) |
No | 27 (25) |
Ligand expression/driver mutation | |
EGFR | 49 (45) |
ALK | 16 (15) |
ROS1 | 2 (2) |
PD-L1 | 5 (5) |
No | 30 (28) |
Unknown | 5 (5) |
Previous systemic treatment lines | 1 (1–5) |
Present metastases | |
≤ 5 | 53 (49) |
> 5 | 55 (51) |
Involved organs | 2 (1–7) |
Status of primary tumor | |
Controlled | 75 (69) |
Progressive | 26 (24) |
Unknown | 7 (7) |
SRT treated lesions | |
Brain | 144 (75) |
Lymph nodes | 3 (2) |
Lung | 18 (9) |
Liver | 6 (3) |
Adrenal gland | 3 (2) |
Bone | 17 (9) |
Soft tissue | 1 (0.5) |
SRT treated lesions per patient | |
Cranial | 1 (1–5) |
Extracranial | 1 (1–3) |
Type of systemic therapy | |
EGFR/ALK-inhibitor | 65 (60) |
PD-1/PD-L1-inhibitor | 33 (31) |
Anti-VEGF-antibody | 9 (8) |
PARP-inhibitor | 1 (1) |
Prescribed BED10 (Gy) | |
Cranial | 75 (26.6–113.9) |
Extracranial | 95.3 (53.1–180) |
Total GTV volume (cc) | |
Cranial | 1.2 (0.04–15.3) |
Extracranial | 8.4 (0.5–86.1) |